Detalhe da pesquisa
1.
Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
Clin Infect Dis;
2024 Apr 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38657084
2.
Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
J Infect Dis;
226(4): 595-607, 2022 09 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32939546
3.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
PLoS Med;
19(1): e1003865, 2022 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35015777
4.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
PLoS Med;
18(10): e1003813, 2021 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34714820
5.
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.
Hum Vaccin Immunother;
20(1): 2327747, 2024 Dec 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38523332
6.
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.
Vaccines (Basel);
12(2)2024 Feb 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38400193
7.
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.
Vaccines (Basel);
12(5)2024 May 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38793748
8.
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.
Front Immunol;
14: 1215302, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37727795
9.
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.
Vaccines (Basel);
11(8)2023 Aug 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37631885
10.
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory.
EBioMedicine;
91: 104562, 2023 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37099841
11.
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
Vaccine;
41(50): 7573-7580, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37981473
12.
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
Lancet Infect Dis;
23(3): 352-360, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36273490
13.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
Lancet Glob Health;
11(11): e1743-e1752, 2023 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37858585
14.
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
PLoS One;
17(10): e0274906, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36197845
15.
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
NPJ Vaccines;
7(1): 156, 2022 Nov 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36450746
16.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
Lancet Infect Dis;
22(1): 110-122, 2022 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34529962
17.
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Lancet Infect Dis;
22(1): 97-109, 2022 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34529963
18.
Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.
NPJ Vaccines;
6(1): 157, 2021 Dec 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34930928
19.
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Lancet Infect Dis;
21(4): 493-506, 2021 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33217361